Latest Conference Articles

October 9th 2017, 11:34pm

NCCN Hematologic Malignancies Congress

Defined composition CAR T cells directed against CD19 have potent anti-tumor activity in B cell malignancies, including acute lymphocytic leukemia.

October 9th 2017, 7:04am

NCCN Hematologic Malignancies Congress

After nearly 40 years with little in the way of drug development for the treatment of acute myeloid leukemia, four new drugs have been approved by the FDA in 2017 for AML, and several promising agents are in development.

October 8th 2017, 11:54pm

NCCN Hematologic Malignancies Congress

The treatment approach for patients with relapsed/refractory multiple myeloma should be tailored based on biology of the disease, frailty of the patient, and comorbidities.

October 8th 2017, 10:55pm

NCCN Hematologic Malignancies Congress

Shaji K. Kumar, MD, discusses proper diagnosis, risk stratification, and personalized medicine for patients with newly-diagnosed multiple myeloma.

October 8th 2017, 9:10pm

NCCN Hematologic Malignancies Congress

Ruben Mesa, chair of the Division of Hematology and Medical Oncology at Mayo Clinic, discusses the guideline updates in polycythemia vera and essential thrombocythemia.

October 8th 2017, 9:04pm

NCCN Hematologic Malignancies Congress

Jane N. Winter, MD, professor of medicine, Division of Hematology/Oncology, Northwestern University, discusses response in follicular lymphoma.

October 8th 2017, 5:31am

NCCN Hematologic Malignancies Congress

In relapsed classical Hodgkin lymphoma, the era of therapies post-brentuximab vedotin is developing rapidly.

October 8th 2017, 3:33am

NCCN Hematologic Malignancies Congress

William G. Wierda, MD, PhD, discusses the continued importance of ibrutinib, the promise for novel combinations, and the impact this progress has had on sequencing for CLL.

October 8th 2017, 12:41am

NCCN Hematologic Malignancies Congress

Survival for patients with grade 1 to 2 follicular lymphoma is now measured in decades to coincide with improvements in therapy.

October 7th 2017, 11:46pm

NCCN Hematologic Malignancies Congress

Shaji K. Kumar, MD, professor of medicine, Mayo Clinic, discusses the management of newly diagnosed patients with multiple myeloma.

October 7th 2017, 11:46pm

NCCN Hematologic Malignancies Congress

William G. Wierda, MD, PhD, medical director of the Leukemia Center at The University of Texas MD Anderson Cancer Center, discusses trials of novel combinations on chronic lymphocytic leukemia.

October 6th 2017, 10:01pm

Global Congress on Bladder Cancer

Robert Jones, MD, discusses the future treatment landscape for patients with urothelial carcinoma in a more multidisciplinary setting.

October 6th 2017, 10:01pm

Global Congress on Bladder Cancer

Eva Comperat, MD, Hospital Tenon, discusses the treatment strategy for patients with neuroendocrine tumors (NETs).

October 6th 2017, 10:01pm

Global Congress on Bladder Cancer

John Wagstaff, MD, professor at Swansea University Medical School, discusses the survival benefit of immunotherapy for patients with bladder cancer.

October 6th 2017, 9:47pm

Global Congress on Bladder Cancer

Delivering IMRT to the bladder and pelvic nodes in patients with node-positive bladder cancer or high-risk node-negative bladder cancer is feasible with patients experiencing low toxicity and demonstrating low pelvic nodal rates of recurrence

October 6th 2017, 9:38pm

Global Congress on Bladder Cancer

A new procedure for monitoring RNA indicators of disease recurrence in urine samples from patients with a history of non-muscle invasive bladder cancer could spare these patients from undergoing multiple cystoscopies during routine follow-up.

October 6th 2017, 1:37am

Global Congress on Bladder Cancer

Although immunotherapy shows great promise in meeting the need for effective treatment of muscle invasive bladder cancer, chemotherapy continues to be an important tool in treating patients with this disease and other forms of bladder and urothelial cancer.

October 6th 2017, 12:21am

Global Congress on Bladder Cancer

Badrinath Konety, MD, MBA, department chair, Department of Urology, University of Minnesota, discusses the guidelines for the management of patients with bladder cancer.

October 6th 2017, 12:19am

Global Congress on Bladder Cancer

Maria De Santis, MD, associate clinical professor at the University of Warwick, discusses the future treatment landscape for patients with bladder cancer.

October 5th 2017, 11:40pm

Global Congress on Bladder Cancer

Andrea Necchi, MD, discusses the current role of immunotherapy and chemotherapy for patients with muscle-invasive bladder cancer.